Aimmune’s PALFORZIA obtains EC’s approval for treating peanut allergies
Author : Saipriya Iyer | Published Date : 2020-12-22
In recent developments, U.S.-based biopharmaceutical company Aimmune Therapeutics Inc. has reportedly received approval from the European Commission (EC) for using its oral immunotherapy, PALFORZIA to treat individuals with peanut allergy.
For the uninitiated, PALFORZIA is a biologic drug that is administered with a systematic dosage approach based on oral immunotherapy (OIT). The process involves the initial ingestion of the specific allergenic proteins in small quantities followed by a gradual increment in the amount to mitigate allergic reactions to the allergen. Furthermore, the drug is produced from a defatted powder of Arachis hypogaea L and is indicated in patients between the age of 4 to 17 years.
The recent development comes after two successful phases 3 clinical trials of the drug, namely Artemis and Palisade, cited sources with relevant information. The oral immunotherapy, in both the trials, met the primary objective and outperformed the placebo results.
President and CEO of Aimmune Therapeutics, Andrew Oxtoby was reported saying that the European Commission’s approval of the treatment is a significant milestone for the company. The company will now focus on launching the product in the United Kingdom and Germany in May 2021, he added.
Meanwhile, Greg Behar, CEO of Nestlé Health Science S.A., commented that the EC approval is the first treatment approved for peanut allergy in the European Union.
Reportedly, around 17 million people across Europe are affected by food allergies, among which peanut allergy is of the highest prevalence. Approximately 1.6% of European children develop the allergy at an early stage and are subject to life-threatening symptoms.
About Aimmune Therapeutics Inc.
Aimmune Therapeutics is a subsidiary of Nestlé Health Science S.A that functions as a clinical-stage biopharmaceutical firm. The California-headquartered organization focuses on commercializing and developing treatments for potentially life-threatening food allergies as well as other food-mediated ailments, primarily gastrointestinal conditions.
Source credits –
About Author
Saipriya Iyer . .
Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i
Related News
Hero MotoCorp under investigation by Ministry of Corporate Affairs
The Indian Ministry of Corporate Affairs has reportedly ordered a probe into Hero MotoCorp to examine its association with an external vendor regarding alleged fund diversion. The objective of the investigation, conducted in the "public interest," is to evaluate the Hero MotoCorp owners... Read More>>
UK: Residents receive bills of up to £49,000 after Ovo acquires SSE
Customers of Ovo, the energy supplier were reportedly left shocked when they received energy bills of up to £49,000, due to data errors that led to overinflated energy bills for some residents. Ovo accepted that some of its customers have been affected by erroneous meter readings, and it bl... Read More>>
Bob Iger returns to Disney as CEO less than a year post retirement
Bob Iger, the ex-CEO of Walt Disney Co., is reportedly coming back to the mass media giant less than a year after his retirement. The surprise announcement comes at a time when Disney is struggling to earn profits from its streaming TV services. According to a statement released by Disney late Su... Read More>>